Atea Pharmaceuticals, Inc. (AVIR) valuation

Special situation detected — historical normalisation may not reflect go-forward economics. EPV and Reverse-DCF outputs below are anchored on history that no longer represents the entity going forward (net cash > 50% of market cap) . Inspect the balance sheet, recent 8-K filings, and the cards above before relying on these models.

• net cash > 50% of market cap. Net cash $255.4M (cash $256.0M − debt $634000) = 59.3% of market cap $430.5M